Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 20

1.

A hypusine-eIF5A-PEAK1 switch regulates the pathogenesis of pancreatic cancer.

Fujimura K, Wright T, Strnadel J, Kaushal S, Metildi C, Lowy AM, Bouvet M, Kelber JA, Klemke RL.

Cancer Res. 2014 Nov 15;74(22):6671-81. doi: 10.1158/0008-5472.CAN-14-1031. Epub 2014 Sep 26.

2.

Autoantibodies to Ezrin are an early sign of pancreatic cancer in humans and in genetically engineered mouse models.

Capello M, Cappello P, Linty FC, Chiarle R, Sperduti I, Novarino A, Salacone P, Mandili G, Naccarati A, Sacerdote C, Beghelli S, Bersani S, Barbi S, Bassi C, Scarpa A, Nisticò P, Giovarelli M, Vineis P, Milella M, Novelli F.

J Hematol Oncol. 2013 Sep 6;6:67. doi: 10.1186/1756-8722-6-67.

3.

Sulindac inhibits pancreatic carcinogenesis in LSL-KrasG12D-LSL-Trp53R172H-Pdx-1-Cre mice via suppressing aldo-keto reductase family 1B10 (AKR1B10).

Li H, Yang AL, Chung YT, Zhang W, Liao J, Yang GY.

Carcinogenesis. 2013 Sep;34(9):2090-8. doi: 10.1093/carcin/bgt170. Epub 2013 May 20.

4.
5.

Evaluation of a gene-directed enzyme-product therapy (GDEPT) in human pancreatic tumor cells and their use as in vivo models for pancreatic cancer.

Hlavaty J, Petznek H, Holzmüller H, Url A, Jandl G, Berger A, Salmons B, Günzburg WH, Renner M.

PLoS One. 2012;7(7):e40611. doi: 10.1371/journal.pone.0040611. Epub 2012 Jul 16.

6.

Aberrant signaling pathways in pancreatic cancer: a two compartment view.

McCleary-Wheeler AL, McWilliams R, Fernandez-Zapico ME.

Mol Carcinog. 2012 Jan;51(1):25-39. doi: 10.1002/mc.20827.

7.

Inhibition of chronic pancreatitis and pancreatic intraepithelial neoplasia (PanIN) by capsaicin in LSL-KrasG12D/Pdx1-Cre mice.

Bai H, Li H, Zhang W, Matkowskyj KA, Liao J, Srivastava SK, Yang GY.

Carcinogenesis. 2011 Nov;32(11):1689-96. doi: 10.1093/carcin/bgr191. Epub 2011 Aug 22.

8.

Intratumor T helper type 2 cell infiltrate correlates with cancer-associated fibroblast thymic stromal lymphopoietin production and reduced survival in pancreatic cancer.

De Monte L, Reni M, Tassi E, Clavenna D, Papa I, Recalde H, Braga M, Di Carlo V, Doglioni C, Protti MP.

J Exp Med. 2011 Mar 14;208(3):469-78. doi: 10.1084/jem.20101876. Epub 2011 Feb 21.

9.

Intraductal papillary-mucinous neoplasia of the pancreas: Histopathology and molecular biology.

Verbeke CS.

World J Gastrointest Surg. 2010 Oct 27;2(10):306-13. doi: 10.4240/wjgs.v2.i10.306.

10.

The epidermal growth factor receptor inhibitor gefitinib prevents the progression of pancreatic lesions to carcinoma in a conditional LSL-KrasG12D/+ transgenic mouse model.

Mohammed A, Janakiram NB, Li Q, Madka V, Ely M, Lightfoot S, Crawford H, Steele VE, Rao CV.

Cancer Prev Res (Phila). 2010 Nov;3(11):1417-26. doi: 10.1158/1940-6207.CAPR-10-0038.

11.

Detection of early-stage pancreatic adenocarcinoma.

Gold DV, Goggins M, Modrak DE, Newsome G, Liu M, Shi C, Hruban RH, Goldenberg DM.

Cancer Epidemiol Biomarkers Prev. 2010 Nov;19(11):2786-94. doi: 10.1158/1055-9965.EPI-10-0667. Epub 2010 Sep 1.

12.

Development of an orthotopic model of invasive pancreatic cancer in an immunocompetent murine host.

Tseng WW, Winer D, Kenkel JA, Choi O, Shain AH, Pollack JR, French R, Lowy AM, Engleman EG.

Clin Cancer Res. 2010 Jul 15;16(14):3684-95. doi: 10.1158/1078-0432.CCR-09-2384. Epub 2010 Jun 9.

13.

Anti-inflammatory effects of the Nigella sativa seed extract, thymoquinone, in pancreatic cancer cells.

Chehl N, Chipitsyna G, Gong Q, Yeo CJ, Arafat HA.

HPB (Oxford). 2009 Aug;11(5):373-81. doi: 10.1111/j.1477-2574.2009.00059.x.

14.

Targeting AKT with the proapoptotic peptide, TAT-CTMP: a novel strategy for the treatment of human pancreatic adenocarcinoma.

Simon PO Jr, McDunn JE, Kashiwagi H, Chang K, Goedegebuure PS, Hotchkiss RS, Hawkins WG.

Int J Cancer. 2009 Aug 15;125(4):942-51. doi: 10.1002/ijc.24424.

15.

The molecular biology of pancreatic cancer.

Abramson MA, Jazag A, van der Zee JA, Whang EE.

Gastrointest Cancer Res. 2007;1(4 Suppl 2):S7-S12.

16.

KRAS2 mutations in human pancreatic acinar-ductal metaplastic lesions are limited to those with PanIN: implications for the human pancreatic cancer cell of origin.

Shi C, Hong SM, Lim P, Kamiyama H, Khan M, Anders RA, Goggins M, Hruban RH, Eshleman JR.

Mol Cancer Res. 2009 Feb;7(2):230-6. doi: 10.1158/1541-7786.MCR-08-0206. Epub 2009 Feb 10.

17.

Trp53 deletion stimulates the formation of metastatic pancreatic tumors.

Morton JP, Klimstra DS, Mongeau ME, Lewis BC.

Am J Pathol. 2008 Apr;172(4):1081-7. doi: 10.2353/ajpath.2008.070778. Epub 2008 Feb 29.

18.

Histological complexities of pancreatic lesions from transgenic mouse models are consistent with biological and morphological heterogeneity of human pancreatic cancer.

Liao JD, Adsay NV, Khannani F, Grignon D, Thakur A, Sarkar FH.

Histol Histopathol. 2007 Jun;22(6):661-76. doi: 10.14670/HH-22.661. Review.

19.

Characterization of pancreatic lesions from MT-tgf alpha, Ela-myc and MT-tgf alpha/Ela-myc single and double transgenic mice.

Liao DJ, Wang Y, Wu J, Adsay NV, Grignon D, Khanani F, Sarkar FH.

J Carcinog. 2006 Jul 5;5:19.

20.

In vivo disruption of TGF-beta signaling by Smad7 leads to premalignant ductal lesions in the pancreas.

Kuang C, Xiao Y, Liu X, Stringfield TM, Zhang S, Wang Z, Chen Y.

Proc Natl Acad Sci U S A. 2006 Feb 7;103(6):1858-63. Epub 2006 Jan 27.

Supplemental Content

Support Center